Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients ; volume:115 ; number:2 ; day:23 ; month:7 ; year:2008 ; pages:359-363 ; date:5.2009
Breast cancer research and treatment ; 115, Heft 2 (23.7.2008), 359-363, 5.2009
- Creator
-
Byrski, T.
Huzarski, T.
Dent, R.
Gronwald, J.
Zuziak, D.
Cybulski, C.
Kladny, J.
Gorski, B.
Lubinski, J.
Narod, S. A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-008-0128-9
- URN
-
urn:nbn:de:101:1-2021081510050304575127
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Byrski, T.
- Huzarski, T.
- Dent, R.
- Gronwald, J.
- Zuziak, D.
- Cybulski, C.
- Kladny, J.
- Gorski, B.
- Lubinski, J.
- Narod, S. A.
- SpringerLink (Online service)
Other Objects (12)
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Cisplatin in breast cancer treatment in BRCA1 carriers
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Cisplatin in breast cancer treatment in BRCA1 carriers
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
Cisplatin in breast cancer treatment in BRCA1 carriers
Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review
Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers